Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498573 | 1.00 | TSHR (0.44) | TSHRFAAHTRPV1TERTPTPN1 | |
| SCHEMBL4493890 | 1.00 | TSHR (0.44) | TSHRFAAHTRPV1TERTPTPN1 | |
| SCHEMBL2152707 | 1.00 | TSHR (0.44) | TSHRFAAHTRPV1TERTPTPN1 | |
| SCHEMBL4489924 | 1.00 | TSHR (0.44) | TSHRFAAHTRPV1TERTPTPN1 | |
| SCHEMBL27637097 | 1.00 | TSHR (0.44) | TSHRFAAHTRPV1TERTPTPN1 | |
| SCHEMBL2152601 | 0.98 | TSHR (0.41) | TSHRFAAHTRPV1TERTPTPN1 | |
| SCHEMBL4500153 | 0.91 | TSHR (0.40) | TSHR | |
| SCHEMBL2152975 | 0.81 | — | — | |
| SCHEMBL129125 | 0.78 | TSHR (0.39) | TSHRFAAHTRPV1TERTPTPN1 | |
| SCHEMBL1092254 | 0.78 | TSHR (0.39) | TSHRFAAHTRPV1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| CN-103130739-B | There is the compound of thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2015-09-16 | — | — | CN | disclosed |
| CN-102796058-B | Compound having thrombopoietin receptor agonism | SHIONOGI & CO | 2015-05-13 | — | — | CN | disclosed |
| CN-103130739-A | Compounds having thrombopoietin receptor agonism | SHIONOGI & CO | 2013-06-05 | — | — | CN | disclosed |
| CN-102796058-A | Compound having thrombopoietin receptor agonism | SHIONOGI & CO | 2012-11-28 | — | — | CN | disclosed |
| CN-102271732-A | Nanochannel devices and related methods | — | 2011-12-07 | — | — | CN | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| CN-1863783-A | Compounds with Thrombopoietin Receptor Agonism | SHIONOGI & CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | TSHR 9/4885FAAH 891/4885TRPV1 781/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | TSHR 757/4885FAAH 1399/4885TRPV1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.